ICDs Have Come a Long Way in 40 Years

Michel Mirowski and his colleagues gave the field of implantable cardioverter-defibrillators (ICDs) a pretty good start, but what's more impressive is how far the technology has advanced since that first human ICD implant in February 1980. In the past 40 years we've seen ICDs become dramatically smaller, longer lasting, more capable, more personalized, subcutaneous (non-transvenous), and even MRI-firendly. And that's not to mention the advanced data connectivity and monitoring capabilities that the latest technologies offer. So without further ado, let's take a look at the current ICD landscape and the companies that are leading this important market. Boston Scientific's S-ICD Continues to Dominate Boston Scientific changed the ICD field considerably when it came out with its Emblem subcutaneous ICD (S-ICD), which offers many patients cardiac defibrillation without transvenous leads. Leads can come with complications, such as migration and perforation, and attempts to remove leads can also be risky. The device won the Prix Galien "Best Medical Technology" award in 2013. The S-ICD is mplanted subcutaneously and runs a lead outside of the sternum, not touching the heart. In 2016, FDA approved the third-generation Embelem MRI S-ICD, an MR-conditional device. In May 2019, Boston Scientific announced acute results from its UNTOUCHED study evaluating the safety and efficacy of the Emblem S-ICD for p...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news